BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1189 related articles for article (PubMed ID: 34374784)

  • 1. Antifungal susceptibility testing with YeastONE™ is not predictive of clinical outcomes of Cryptococcus neoformans var. grubii fungemia.
    Yang JH; Huang PY; Cheng CW; Shie SS; Lin ZF; Yang LY; Lee CH; Wu TS
    Med Mycol; 2021 Nov; 59(11):1114-1121. PubMed ID: 34374784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
    Chowdhary A; Randhawa HS; Sundar G; Kathuria S; Prakash A; Khan Z; Sun S; Xu J
    J Med Microbiol; 2011 Jul; 60(Pt 7):961-967. PubMed ID: 21393452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predominance of Cryptococcus neoformans var. grubii multilocus sequence type 5 and emergence of isolates with non-wild-type minimum inhibitory concentrations to fluconazole: a multi-centre study in China.
    Fan X; Xiao M; Chen S; Kong F; Dou HT; Wang H; Xiao YL; Kang M; Sun ZY; Hu ZD; Wan Z; Chen SL; Liao K; Chu YZ; Hu TS; Zou GL; Hou X; Zhang L; Zhao YP; Xu YC; Liu ZY
    Clin Microbiol Infect; 2016 Oct; 22(10):887.e1-887.e9. PubMed ID: 27432767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of Sensititre YeastOne and VITEK 2 against the Clinical and Laboratory Standards Institute M27-E4 reference broth microdilution method for the antifungal susceptibility testing of Cryptococcus neoformans and Cryptococcus gattii.
    Zhang M; Zhou Z; Wang D; Zhou A; Song G; Chen X; Guo J; Wu W
    Med Mycol; 2022 Mar; 60(3):. PubMed ID: 35099022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans.
    Yang F; Gritsenko V; Lu H; Zhen C; Gao L; Berman J; Jiang YY
    Microbiol Spectr; 2021 Oct; 9(2):e0072321. PubMed ID: 34585947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
    Nascimento E; Vitali LH; Kress MRVZ; Martinez R
    Rev Inst Med Trop Sao Paulo; 2017; 59():e49. PubMed ID: 28793019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
    Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Al-Odaini N; Li XY; Li BK; Chen XC; Huang CY; Lv CY; Pan KS; Zheng DY; Zheng YQ; Liao WQ; Cao CW
    Front Microbiol; 2021; 12():708280. PubMed ID: 34447360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017.
    Selb R; Fuchs V; Graf B; Hamprecht A; Hogardt M; Sedlacek L; Schwarz R; Idelevich EA; Becker SL; Held J; Küpper-Tetzel CP; McCormick-Smith I; Heckmann D; Gerkrath J; Han CO; Wilmes D; Rickerts V
    Int J Med Microbiol; 2019 Sep; 309(6):151336. PubMed ID: 31444102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Prevalence of HIV-Related Cryptococcosis and Increased Resistance to Fluconazole of the
    Yang C; Bian Z; Blechert O; Deng F; Chen H; Li Y; Yang Y; Chen M; Zhan P
    Front Cell Infect Microbiol; 2021; 11():723251. PubMed ID: 34790585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbiological and clinical characteristics of cryptococcemia: a retrospective analysis of 85 cases in a Chinese hospital.
    Fu Y; Xu M; Zhou H; Yao Y; Zhou J; Pan Z
    Med Mycol; 2020 Jun; 58(4):478-484. PubMed ID: 31504739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
    Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
    Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro synergistic effect of minocycline combined with antifungals against Cryptococcus neoformans.
    Tan L; Shi H; Chen M; Wang Z; Yao Z; Sun Y
    J Mycol Med; 2022 Mar; 32(1):101227. PubMed ID: 34800920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F; Hare Jensen R; Meis JF; Arendrup MC
    Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The epidemiology of cryptococcosis and the characterization of Cryptococcus neoformans isolated in a Brazilian University Hospital.
    Aguiar PADF; Pedroso RDS; Borges AS; Moreira TA; Araújo LB; Röder DVDB
    Rev Inst Med Trop Sao Paulo; 2017 Apr; 59():e13. PubMed ID: 28423088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
    Gutch RS; Nawange SR; Singh SM; Yadu R; Tiwari A; Gumasta R; Kavishwar A
    Braz J Microbiol; 2015; 46(4):1125-33. PubMed ID: 26691471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced Susceptibility to Azoles in Cryptococcus gattii Correlates with the Substitution R258L in a Substrate Recognition Site of the Lanosterol 14-α-Demethylase.
    Carvajal SK; Melendres J; Escandón P; Firacative C
    Microbiol Spectr; 2023 Aug; 11(4):e0140323. PubMed ID: 37341584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbiological characteristics of clinical isolates of Cryptococcus neoformans in Taiwan: serotypes, mating types, molecular types, virulence factors, and antifungal susceptibility.
    Liaw SJ; Wu HC; Hsueh PR
    Clin Microbiol Infect; 2010 Jun; 16(6):696-703. PubMed ID: 19694765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotyping and antifungal susceptibility testing of Cryptococcus neoformans isolates from Cameroonian HIV-positive adult patients.
    Bertout S; Drakulovski P; Kouanfack C; Krasteva D; Ngouana T; Dunyach-Rémy C; Dongtsa J; Aghokeng A; Delaporte E; Koulla-Shiro S; Reynes J; Mallié M
    Clin Microbiol Infect; 2013 Aug; 19(8):763-9. PubMed ID: 23033854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular epidemiology and antifungal susceptibilities of Cryptococcus species isolates from HIV and non-HIV patients in Southwest China.
    Wu SY; Kang M; Liu Y; Chen ZX; Xiao YL; He C; Ma Y
    Eur J Clin Microbiol Infect Dis; 2021 Feb; 40(2):287-295. PubMed ID: 32895755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.